Lv4
720 积分 2021-07-06 加入
Hijacking ERAD for targeted degradation of transmembrane proteins
12天前
已完结
Structure-Based Design of 4-(1-Methyl-1H-indol-3-yl)pyrimidin-2-amine Derivatives as the First Covalent FGFR3 Selective Inhibitors
1个月前
已完结
Pemigatinib for Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement
2个月前
已完结
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
2个月前
已完结
Oral Infigratinib Therapy in Children with Achondroplasia
2个月前
已完结
RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity acrossFGFR2Alterations and Resistance Mutations
2个月前
已完结
Structural and Functional Diversity in the FGf Receptor Multigene Family
2个月前
已完结
Structural and Functional Diversity in the FGf Receptor Multigene Family
2个月前
已关闭
Structural and Functional Diversity in the FGf Receptor Multigene Family
2个月前
已关闭
Discovery of 2-Amino-7-sulfonyl-7H-pyrrolo[2,3-d]pyrimidine Derivatives as Potent Reversible FGFR Inhibitors with Gatekeeper Mutation Tolerance: Design, Synthesis, and Biological Evaluation
3个月前
已完结
皖公网安备34019202002308
